Clinical Trials Browser

Completed × Interventional × pemigatinib × Clear all

Neoplasms, Unknown Primary

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Phase 2 Completed

47 enrolled 21 charts 1 FDA

Myeloid

Eosinophilia, Myeloproliferative Disorders

NCT03914794 2025-10-03

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Phase 2 Completed

30 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Phase 2 Completed

263 enrolled 20 charts

Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Phase 2 Completed

147 enrolled 22 charts 1 FDA

Gastrointestinal

Acrocephalosyndactylia, Cholangiocarcinoma

NCT05253807 2025-08-05

FIGHT-210

Phase 2 Completed

8 enrolled 13 charts

Thoracic

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04256980 2024-05-30

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Phase 2 Completed

34 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT05529667 2024-05-08

Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

Phase 1/2 Completed

15 enrolled

Gastrointestinal

Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel

NCT04258527 2021-07-23

Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations

Phase 1 Completed

12 enrolled

Other solid neoplasm

Solid Tumor

NCT03235570 2020-05-29

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

Phase 1 Completed

44 enrolled

Acrocephalosyndactylia, Neoplasms

Clinical Trials

CUPISCO

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

FIGHT-210

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)